Artificial intelligence (AI) company Opyl has launched a new AI software platform that can predict the success or failure of vaccines or antibody therapies targeting COVID-19 in clinical trials. Opyl’s AI forecasting model has examined 475 registered COVID-19 trials across the globe to help predict the drugs or devices that have the greatest chance of success.

The platform has predicted that the COVID-19 therapies have a much higher chance of approval than do the vaccines being studied and that an antibody therapy has the highest probability of a positive phase 3 outcome over all other therapies being studied.